Aryx Therapeutics OTC Pink Sheet Analysis

ARYX
 Stock
  

USD 0.0005  0.00  0.00%   

The current indifference towards the small price fluctuations of Aryx Therapeutics could raise concerns from investors as the firm is trading at a share price of 5.0E-4 on very low momentum in volume. The company directors and management did not add any value to Aryx Therapeutics investors in November. However, most investors can still diversify their portfolios with Aryx Therapeutics to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently very low. The very small Stock volatility is a good signal to investors with longer-term investment horizons.
Please continue to Trending Equities.
  
The Aryx Therapeutics otc pink sheet analysis report makes it easy to digest most publicly released information about Aryx Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Aryx Therapeutics OTC Pink Sheet analysis module also helps to analyze the Aryx Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Aryx Therapeutics OTC Pink Sheet Analysis Notes

The company recorded a loss per share of 0.59. Aryx Therapeutics had not issued any dividends in recent years. ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. ARYX THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on PNK Exchange. It employs 56 people.The quote for Aryx Therapeutics I is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Aryx Therapeutics I please contact Paul Goddard at 510 585 2200 or go to https://www.aryx.com.

Aryx Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more otcs at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aryx Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aryx Therapeutics I or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aryx Therapeutics generated a negative expected return over the last 90 days
Aryx Therapeutics has some characteristics of a very speculative penny stock
The company has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx Therapeutics to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (33.17 M) with profit before overhead, payroll, taxes, and interest of 0.
Aryx Therapeutics I currently holds about 2.95 M in cash with (34.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Aryx Therapeutics Market Capitalization

The company currently falls under 'Nano-Cap' category with current market capitalization of 237.58 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aryx Therapeutics's market, we take the total number of its shares issued and multiply it by Aryx Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (0.7486) % which means that it has lost $0.7486 on every $100 spent on asset. This is way below average. Aryx Therapeutics management efficiency ratios could be used to measure how well aryx therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

Aryx Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Aryx Therapeutics I, which can be compared to its rivals. Please confirm Aryx Therapeutics jensen alpha and semi variance to decide if Aryx Therapeutics is priced correctly, providing market reflects its regular price of 5.0E-4 per share. As Aryx Therapeutics appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Aryx Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. Aryx Therapeutics Triple Exponential Moving Average indicator shows smoothing effect of Aryx Therapeutics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

Aryx Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aryx Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aryx Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aryx Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Aryx Therapeutics Technical and Predictive Indicators

Aryx Therapeutics Forecast Models

Aryx Therapeutics time-series forecasting models is one of many Aryx Therapeutics' otc pink sheet analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aryx Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Aryx Therapeutics OTC Pink Sheet Analysis

OTC Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Aryx Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aryx Therapeutics shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual OTC such as Aryx Therapeutics. By using and applying Aryx Therapeutics OTC Pink Sheet analysis, traders can create a robust methodology for identifying Aryx Therapeutics entry and exit points for their positions.
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. ARYX THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on PNK Exchange. It employs 56 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc pink sheet analysis tools, you can find out how much better you can do when adding Aryx Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Content Syndication Now

   

Content Syndication

Quickly integrate customizable finance content to your own investment portal
All  Next Launch Module
Please continue to Trending Equities. You can also try Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for analysis

When running Aryx Therapeutics price analysis, check to measure Aryx Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aryx Therapeutics is operating at the current time. Most of Aryx Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aryx Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aryx Therapeutics' price. Additionally, you may evaluate how the addition of Aryx Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Please note, there is a significant difference between Aryx Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Aryx Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aryx Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.